



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

EMA/627976/2010

## European Medicines Agency decision

P/220/2010

of 29 October 2010

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for 12 grass pollen extract, cultivated rye pollen extract and birch/alder/hazel pollen extract, (EMA-000812-PIP01-09) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

### **Disclaimer**

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

**Only the English text is authentic.**



# European Medicines Agency decision

P/220/2010

of 29 October 2010

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for 12 grass pollen extract, cultivated rye pollen extract and birch/alder/hazel pollen extract, (EMEA-000812-PIP01-09) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004<sup>1</sup>,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency<sup>2</sup>,

Having regard to the application submitted by Allergy Therapeutics (UK) Ltd on 8 January 2010 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 10 September 2010, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.
- (4) It is therefore appropriate to adopt a decision granting a waiver.

---

<sup>1</sup> OJ L 378, 27.12.2006, p.1.

<sup>2</sup> OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

**Article 1**

A paediatric investigation plan for 12 grass pollen extract, cultivated rye pollen extract and birch/alder/hazel pollen extract, suspension for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

**Article 2**

A deferral for 12 grass pollen extract, cultivated rye pollen extract and birch/alder/hazel pollen extract, suspension for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

**Article 3**

A waiver for 12 grass pollen extract, cultivated rye pollen extract and birch/alder/hazel pollen extract, suspension for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

**Article 4**

This decision is addressed to Allergy Therapeutics (UK) Ltd, Dominion Way, Worthing, West Sussex BN14 8SA, United Kingdom.

Done at London, 29 October 2010

For the European Medicines Agency  
Thomas Lönnngren  
Executive Director

(Signature on file)



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

EMA/PDCO/532417/2010

## Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMA-000812-PIP01-09

### Scope of the application

**Active substance(s):**

12 grass pollen extract, cultivated rye pollen extract and birch/alder/hazel pollen extract

**Condition(s):**

Treatment of allergic rhinitis/rhino-conjunctivitis

**Pharmaceutical form(s):**

Suspension for injection

**Route(s) of administration:**

Subcutaneous use

**Name/corporate name of the PIP applicant:**

Allergy Therapeutics (UK) Ltd

### Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Allergy Therapeutics (UK) Ltd submitted for agreement to the European Medicines Agency on 8 January 2010 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 18 February 2010.

Supplementary information was provided by the applicant on 25 June 2010.



## Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 18 of said Regulation,
- to grant a deferral in accordance with Article 21 of said Regulation ,
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex(es) and appendix.

London, 10 September 2010

On behalf of the Paediatric Committee  
Dr Daniel Brasseur, Chairman

(Signature on file)

## **Annex I**

**The measures and timelines of the agreed Paediatric Investigation Plan and the subset(s) of the paediatric population and condition(s) covered by the waiver**

# 1. Waiver

Treatment of allergic rhinitis/rhino-conjunctivitis

## 1.1. Condition(s)

Treatment of allergic rhinitis/rhino-conjunctivitis

The waiver applies to:

- Children from birth to less than 5 years of age
- for suspension for injection, subcutaneous use
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

# 2. Paediatric Investigation Plan

## 2.1. Condition

Treatment of rhinitis/rhino-conjunctivitis

### 2.1.1. Indication(s) targeted by the PIP

Treatment of allergic rhinitis/rhino-conjunctivitis

### 2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 5 to less than 18 years of age.

### 2.1.3. Pharmaceutical form(s)

Suspension for injection, subcutaneous use

### 2.1.4. Studies

Area	Number of studies	Description
Quality		Not applicable.
Non-clinical		Not applicable.
Clinical	1	303P: A double blind, randomized, multicentre, placebo-controlled trial to evaluate long term efficacy and safety/tolerability of MATA Grass/Birch + MPL in paediatric subjects aged 5 to less than 18 years of age for the treatment of allergic rhino-conjunctivitis.

### 3. Follow-up, completion and deferral of PIP

Measures to address long term follow-up of potential safety issues and efficacy in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By Feb 2022
Deferral for one or more studies contained in the paediatric investigation plan:	Yes